Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High

Cidara Therapeutics (CDTX) shares surged over 17% to a five-year high, extending its significant year-to-date gains, after announcing accelerated Phase 3 testing for its non-vaccine flu prevention drug, CD388, following a positive FDA meeting. The company now anticipates a single final-phase study could be sufficient for approval, prompting RBC Capital Markets to raise its price target to $137 and project $3.78 billion in worldwide sales for CD388 in the out-years, highlighting substantial revenue potential from the expedited development timeline.

Analysis

Cidara Therapeutics (CDTX) shares surged over 17% to a five-year high of 86.11, extending a year-to-date rally that has already exceeded 173%. The primary catalyst for this move is the company's announcement of an accelerated development timeline for its non-vaccine flu prevention drug, CD388, following a productive meeting with the U.S. Food and Drug Administration. The plan to initiate Phase 3 testing six months earlier to align with the Northern Hemisphere's flu season, combined with the potential for approval based on a single final-phase study, significantly de-risks the asset and shortens its path to market. This outlook is reinforced by RBC Capital Markets, which raised its price target on CDTX to $137 from $115, projecting potential worldwide sales of $3.78 billion in the out-years. The stock's fundamental momentum is further evidenced by its perfect IBD Digital Relative Strength Rating of 99, indicating it is in the top 1% of stocks for price performance over the last 12 months.

Key Decisions for Investors

• The accelerated Phase 3 timeline and potential for a single-study approval pathway for CD388 significantly enhance the asset's profile, warranting consideration for investors with a high-risk tolerance for clinical-stage biotechnology.
• Investors should closely monitor future milestones, particularly the formal initiation of the Phase 3 trial and subsequent data readouts, as these will be the next major catalysts validating the drug's multi-billion dollar sales potential.
• Given the stock's rapid appreciation of over 173% year-to-date, investors may consider the heightened valuation and inherent clinical trial risks, while acknowledging the substantial upside indicated by the analyst's $137 price target.